Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab.

Journal: BMJ open
PMID: 40355288

Abstract

OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease. Chest high-resolution CT (HRCT) is instrumental in IPF management, and the Quantitative Lung Fibrosis (QLF) score is a computer-assisted metric for quantifying lung disease using HRCT. This study aimed to assess the change in QLF score associated with a minimum clinically important difference (MCID) of IPF symptoms and physiological lung function, and also determine the MCID of QLF change associated with all-cause mortality to serve as an imaging biomarker to confirm disease progression and response to therapy.

Authors

  • Grace Hyun Kim
    University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA GraceKim@mednet.ucla.edu.
  • Xueping Zhang
    FibroGen Inc, San Francisco, California, USA.
  • Matthew S Brown
    University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA.
  • Lona Poole
    FibroGen Inc, San Francisco, California, USA.
  • Jonathan Goldin
    University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA.

Keywords

External Resources

Popular Topics
Recent Journals